血管性水腫治療市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、疾病類型、最終用戶和分銷管道分類）

2025 年血管性水腫治療市值為 64.7 億美元，預計到 2026 年將成長至 76.2 億美元，複合年成長率為 18.60%，到 2032 年將達到 213.6 億美元。

主要市場統計數據
基準年 2025	64.7億美元
預計年份：2026年	76.2億美元
預測年份 2032	213.6億美元
複合年成長率 (%)	18.60%

全面概述了血管性水腫的臨床複雜性、診斷進展和治療進展，這些正在改變血管性水腫的治療和相關人員的優先事項。

血管性水腫是一種臨床表現多樣的疾病，其特徵是陣發性組織腫脹、可能危及生命的呼吸道阻塞，以及涵蓋遺傳、免疫和特發性途徑的多種誘發因素。對緩激肽介導路徑的深入理解、診斷演算法的改進以及強調靶向分子干涉的治療方法的拓展，正在重塑現代醫療模式。臨床醫師越來越重視起效迅速、能夠為高風險患者提供持續預防、且可在門診或居家給藥的治療方法，以減少急診醫療需求並提高患者的生活品質。

治療創新、擴大門診護理和不斷變化的法規如何共同作用，重新定義血管性水腫的治療模式和商業性需求？

血管性水腫的治療格局正在經歷一場變革，這主要得益於分子標靶療法的進步、門診治療模式的擴展以及監管環境和支付方期望的轉變。針對緩激肽路徑和激肽釋放酶活性的精準療法正在重新定義臨床終點，相關人員越來越關注的不僅是治療急性發作，還包括降低發作頻率和預防氣道阻塞。同時，患者自行用藥和居家照護的趨勢正在改變產品設計重點，人們越來越重視兼具易用性、安全性和穩定性的製劑和裝置。

對美國血管性水腫藥物關稅導致的供應鏈變化和採購系統調整的營運和策略影響進行評估。

美國關稅趨勢和貿易政策調整將對血管性水腫治療的經濟和物流環節產生重大影響，具體體現在投入成本、進口計畫和供應商選擇等方面。關稅相關的成本壓力增加，往往促使製造商和經銷商調整籌資策略、加快替代供應商的認證流程，或將生產流程在地化以降低跨境關稅風險。這些供應鏈調整可能導致重新評估庫存緩衝、延長複雜生物製藥的前置作業時間，以及轉向更注重可靠性和可預測性的分銷網路。

以細分市場主導的洞察，將治療機制、劑型、疾病異質性、醫療保健環境和分銷管道與可操作的商業化方案聯繫起來。

精細化的市場細分觀點揭示了臨床和商業策略應如何協調一致，以應對特定的治療類別、給藥偏好、疾病病因、醫療機構和通路。對於每類藥物——緩激肽受體拮抗劑、C1抑制劑和激肽釋放酶抑制劑——都需要透過將機制特異性療效與以患者為中心的終點和支付方相關指標聯繫起來，來區分其價值提案。這需要產生有針對性的證據，以證明每種治療方法在降低癲癇發作嚴重程度和改善長期疾病控制方面的相對優勢。基於給藥途徑，市場通常受到注射劑（通常迅速起效）和口服劑（在便利性和依從性方面具有優勢）之間實際權衡的影響。因此，研發人員需要最佳化製劑和給藥技術，以適應預期的醫療機構環境。

制定區域策略，協調美洲、歐洲、中東和非洲以及亞太地區的監管、報銷和准入方法，以最大限度地惠及病患。

區域趨勢對血管性水腫治療藥物的研發重點、監管協調和准入途徑有著至關重要的影響，因此美洲、歐洲、中東和非洲以及亞太地區需要採取差異化的策略。在美洲，相關人員通常致力於證明藥物具有明確的臨床價值，並確保其療效符合支付方的預期，從而確保藥物獲得上市許可並被門診患者接受治療，同時支持居家給藥方案，以減輕急診護理的負擔。該地區的監管審查流程通常建議採用可靠的臨床終點指標和核准後安全性監測，因此，實證策略優先考慮收集真實世界數據。

領先的研發公司如何將以機制為中心的研發組合與給藥創新、供應鏈夥伴關係以及以患者為中心的支援相結合，以實現臨床和商業性應用？

血管性水腫領域主要企業的舉措包括平台投資、針對性臨床開發以及建構商業生態系統。領先的研發公司優先開發針對特定機制的產品組合，同時投資於便於患者自行給藥和門診使用的製劑技術。隨著企業努力降低供應鏈風險並確保生物製藥填充、包裝和低溫運輸配送的可靠管道，與契約製造和物流供應商建立策略合作夥伴關係正變得越來越普遍。

為經營團隊提供切實可行的建議，以整合研發、供應鏈韌性、支付方合作以及以病人為中心的服務，從而持續推廣血管性水腫治療藥物。

產業領導者應採取多管齊下的策略，整合臨床差異化、供應鏈韌性和價值展現，並透過與支付方的合作實現這一目標。首先，優先發展能夠將作用機制與具有臨床意義的終點和患者報告結局（PRO）明確關聯的研發項目，並確保循證方案能夠涵蓋急性和預防性應用場景。其次，投資於能夠實現安全有效居家給藥的劑型和培訓項目，同時最大限度地減輕專科診所和急救服務的負擔。第三，透過認證多家供應商、盡可能探索本地生產夥伴關係以及提高整個分銷鏈的透明度，增強供應鏈的柔軟性並防止中斷。

透過整合二手資料、有針對性的相關人員訪談和嚴格的檢驗，我們高度透明的混合調查方法能夠產生以決策為中心的見解。

本研究途徑結合了系統性的二級文獻綜述、結構化的原始研究以及嚴謹的檢驗，以確保獲得可靠且具有決策意義的見解。二級研究整合了同行評審文獻、監管指導文件、臨床實踐指南以及公開的安全性和有效性數據，以獲得整體情況並識別機制差異。原始研究包括對廣泛的相關人員進行半結構式訪談，這些利益相關者包括免疫學和過敏學專家、採購負責人、醫院和專科診所的臨床管理人員以及患者權益倡導組織的代表，旨在識別推廣應用的障礙以及治療路徑的實際情況。

結論強調了治療創新、交付模式、支付方合作和供應彈性之間的相互作用，這對於血管性水腫治療的實質進展至關重要。

這些分析凸顯了血管性水腫治療領域的一個策略轉折點：分子層面的創新、遞送最佳化和生態系統設計在此交匯融合，為改善患者預後和實現差異化的商業性成功創造了新的機會。標靶治療的進步和對居家照護模式日益成長的關注，正推動臨床實踐向預防性管理轉變；同時，需要採取謹慎的風險緩解策略，以適應供應鍊和政策趨勢並維持藥物的可及性。有效的商業化不僅取決於分子療效，還取決於向支付方證明其價值、為患者提供便利安全的給藥方案，以及確保在各種通路中實現可靠的供應。

目錄

第1章：序言

第2章：調查方法

• 調查設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查的前提
• 研究限制

第3章執行摘要

• 首席體驗長觀點
• 市場規模和成長趨勢
• 2025年市佔率分析
• FPNV定位矩陣，2025
• 新的商機
• 下一代經營模式
• 產業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 波特五力分析
• PESTEL 分析
• 市場展望
• 上市策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會映射
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 血管性水腫治療市場：依藥物類別分類

• 緩激肽受體拮抗劑
• C1抑制劑
• 激肽釋放酶抑制劑

第9章：依給藥途徑分類的血管性水腫治療市場

• 注射藥物
• 口服

第10章 血管性水腫治療市場：依疾病類型分類

• 獲得
• 遺傳
• 特發性

第11章 血管性水腫治療市場：依最終用戶分類

• 居家照護
• 醫院
• 專科診所

第12章 血管性水腫治療市場：依通路分類

• 醫院藥房
• 網路藥房
• 零售藥房

第13章 血管性水腫治療市場：依地區分類

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第14章 血管性水腫治療市場：依組別分類

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第15章 血管性水腫治療市場：依國家分類

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第16章：美國血管性水腫治療市場

第17章 中國血管性水腫治療市場

第18章 競爭格局

• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年
• Adverum Biotechnologies, Inc.
• Argenx NV
• AstraZeneca plc
• Attune Pharmaceuticals, Inc.
• Aurobindo Pharma Ltd.
• Bayer AG
• BioCryst Pharmaceuticals, Inc.
• Cipla Limited
• CSL Behring
• Dr. Reddy's Laboratories Ltd.
• GlaxoSmithKline plc
• HAE Pharma LLC
• Intellia Therapeutics, Inc.
• Ionis Pharmaceuticals, Inc.
• KalVista Pharmaceuticals Ltd.
• Merck & Co., Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Pharming Group NV
• Pharvaris Netherlands BV
• Sanofi SA
• Sobi
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

The Angioedema Treatment Market was valued at USD 6.47 billion in 2025 and is projected to grow to USD 7.62 billion in 2026, with a CAGR of 18.60%, reaching USD 21.36 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 6.47 billion
Estimated Year [2026]	USD 7.62 billion
Forecast Year [2032]	USD 21.36 billion
CAGR (%)	18.60%

An immersive introduction to the clinical complexity, diagnostic evolution, and therapeutic momentum transforming angioedema care and stakeholder priorities

Angioedema presents a heterogeneous clinical challenge characterized by episodic tissue swelling, potentially life-threatening airway compromise, and variable triggers that span genetic, immunologic, and idiopathic pathways. Contemporary care paradigms are being reshaped by a deeper mechanistic understanding of bradykinin-mediated pathways, improved diagnostic algorithms, and an expanding therapeutic armamentarium that emphasizes targeted molecular interventions. Clinicians increasingly prioritize rapid onset of action, durable prophylaxis for high-risk patients, and treatment regimens that support outpatient and home-based administration to reduce emergency utilization and improve quality of life.

Payers and health systems are adapting protocols to balance acute care needs against long-term management costs and patient adherence. Meanwhile, research investments are moving toward precision approaches that seek to stratify patients by underlying disease mechanism and response predictors. Translational efforts now focus on biomarker-driven diagnostics and novel delivery platforms that can address both hereditary and acquired forms of angioedema. Taken together, these forces are driving a transition from episodic rescue therapy toward integrated care pathways that emphasize prophylaxis, personalized treatment selection, and cross-disciplinary coordination among immunology, allergy, and emergency medicine specialists.

How therapeutic innovation, outpatient care expansion, and regulatory evolution are converging to redefine treatment paradigms and commercial imperatives in angioedema

The landscape for angioedema treatment is undergoing transformative shifts driven by advances in molecularly targeted therapies, expanded outpatient care models, and evolving regulatory and payer expectations. Precision therapeutics that target the bradykinin pathway and kallikrein activity are redefining clinical endpoints, with stakeholders increasingly focused on reducing attack frequency and preventing airway compromise rather than merely treating acute episodes. Simultaneously, the move toward self-administration and home-based care is altering product design priorities, favoring formulations and devices that combine ease of use with robust safety and stability profiles.

Regulatory frameworks are also maturing to accommodate novel biologics and small-molecule inhibitors, prompting sponsors to design evidence packages that emphasize patient-reported outcomes and long-term safety. In parallel, digital health tools and remote monitoring are creating opportunities for earlier intervention and improved adherence, enabling tighter integration between specialty clinics and home care providers. These shifts create new competitive dynamics, where value demonstration, real-world evidence generation, and cross-stakeholder alignment will determine which products achieve sustainable uptake across diverse care settings.

Assessing the operational and strategic consequences of tariff-driven supply chain shifts and procurement adaptations for angioedema therapeutics in the United States

Tariff dynamics and trade policy adjustments in the United States can materially influence the economics and logistics of angioedema therapeutics by affecting input costs, import timelines, and supplier selection. When tariff-related cost pressures rise, manufacturers and distributors often respond by reassessing sourcing strategies, accelerating qualification of alternative suppliers, or localizing manufacturing steps to reduce exposure to cross-border duties. These supply chain adaptations can lead to reevaluation of inventory buffers, longer lead times for complex biologics, and shifts in distribution networks that prioritize reliability and predictability.

Healthcare providers and payers may experience indirect effects as procurement processes incorporate new cost and availability considerations, prompting renegotiations of contracts or the exploration of alternative therapeutic classes where clinically appropriate. Manufacturers can mitigate tariff-related disruptions by diversifying supply chains across geographies, investing in onshore fill-finish capabilities, and enhancing transparency with trading partners to anticipate policy shifts. In addition, strategic use of advance purchase commitments and tiered pricing arrangements can preserve access in vulnerable patient populations while maintaining commercial viability under evolving tariff conditions.

Segment-driven insights that connect therapeutic mechanisms, delivery formats, disease heterogeneity, care settings, and distribution channels to pragmatic commercialization choices

A granular segmentation lens reveals how clinical and commercial strategies must align to address distinct therapeutic classes, administration preferences, disease etiologies, care settings, and distribution pathways. Based on drug class, product developers must differentiate value propositions for bradykinin receptor antagonists, C1 inhibitors, and kallikrein inhibitors by linking mechanism-specific outcomes to patient-centric endpoints and payer-relevant measures. This requires targeted evidence generation that speaks to the comparative advantages of each modality in reducing attack severity and improving long-term disease control. Based on administration route, the market is influenced by the practical trade-offs between injectable therapies that often deliver rapid onset and oral agents that offer convenience and adherence benefits; developers must therefore optimize formulation and delivery technology to match intended care settings.

Based on disease type, the needs of patients with acquired, hereditary, and idiopathic forms diverge in diagnostic complexity, genetic counseling requirements, and prophylaxis versus rescue therapy priorities, demanding differentiated clinical pathways and patient education. Based on end user, home care, hospitals, and specialty clinics present unique adoption barriers and training needs, shaping how product support programs and clinical services are structured. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy dynamics influence access, reimbursement pathways, and patient convenience, requiring tailored commercial strategies that account for regulatory, logistical, and payer nuances across each channel.

Regional strategies for aligning regulatory, reimbursement, and access approaches across the Americas, Europe Middle East & Africa, and Asia-Pacific to optimize patient reach

Regional dynamics exert a defining influence on development priorities, regulatory alignment, and access pathways for angioedema treatments, requiring differentiated approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, stakeholder emphasis is commonly placed on demonstrating clear clinical value and payer-aligned outcomes to secure formulary placement and outpatient adoption while also supporting home administration programs that reduce acute care burden. Regulatory review processes in this region often encourage robust clinical endpoints and post-approval safety monitoring, shaping evidence strategies that prioritize real-world data collection.

Across Europe, Middle East & Africa, diverse national regulatory regimes and procurement models necessitate flexible market-entry strategies and tailored health-technology assessment dossiers. Manufacturers must be prepared to engage diverse payer panels and adopt adaptive pricing approaches to accommodate public tendering processes and regional reimbursement variability. In the Asia-Pacific region, rapid innovation adoption in some markets is counterbalanced by infrastructure and access disparities in others, creating opportunities for tiered market entry, local partnerships, and capacity-building initiatives that support training for specialty clinics and home-care networks. Across all regions, coordinated regulatory planning and early payer engagement enhance the likelihood of timely access for patients.

How leading developers are pairing mechanism-focused portfolios with delivery innovations, supply-chain partnerships, and patient-centric support to win clinical and commercial adoption

Key company-level behaviors in the angioedema landscape reflect a combination of platform investment, targeted clinical development, and commercial ecosystem building. Leading developers are prioritizing mechanism-specific portfolios while investing in formulation technologies that facilitate self-administration and outpatient use. Strategic alliances with contract manufacturing and logistics providers are increasingly common as firms seek to de-risk supply chains and secure reliable channels for biologic fill-finish and cold-chain distribution.

Commercially, firms are creating integrated patient support services that combine training, adherence tools, and reimbursement navigation to lower barriers to adoption among home care users and specialty clinics. On the evidence front, sponsors are expanding real-world data programs and patient-reported outcome initiatives to supplement pivotal clinical studies and to meet payer expectations for longitudinal effectiveness and safety. Competitive differentiation is emerging through service models as much as product attributes, with successful organizations demonstrating the ability to align clinical benefits with pragmatic delivery and support systems that resonate with clinicians, payers, and patients alike.

Actionable recommendations for executives to align R&D, supply chain resilience, payer engagement, and patient-centric services for sustainable angioedema product adoption

Industry leaders should adopt a multi-dimensional strategy that integrates clinical differentiation, supply resilience, and payer-aligned value demonstration. First, prioritize development programs that clearly link mechanism of action to clinically meaningful endpoints and patient-reported outcomes, ensuring that evidence generation plans address both acute and prophylactic use cases. Second, invest in delivery formats and training programs that enable safe, effective home administration while minimizing the burden on specialty clinics and emergency services. Third, build supply-chain flexibility by qualifying multiple suppliers, exploring local manufacturing partnerships where feasible, and enhancing visibility across distribution layers to preempt disruptions.

Additionally, engage payers early with transparent value dossiers and real-world evidence plans that demonstrate cost-offsets associated with reduced emergency interventions and improved work productivity. Strengthen commercial propositions by aligning distribution strategies with channel-specific access considerations, coordinating with hospital pharmacies, online dispensaries, and retail networks to optimize availability. Finally, develop service-oriented differentiation-patient support, digital adherence tools, and clinician education-to accelerate uptake and sustain long-term adherence across diverse patient cohorts.

A transparent mixed-methods methodology integrating secondary synthesis, targeted stakeholder interviews, and rigorous triangulation to produce decision-focused insights

The research approach combines systematic secondary review, structured primary inquiry, and rigorous triangulation to ensure robust, decision-grade findings. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical practice statements, and publicly available safety and efficacy data to map the clinical landscape and identify mechanistic differentiators. Primary research involved semi-structured interviews with a cross-section of stakeholders, including specialists in immunology and allergy, procurement officials, clinical operations leaders from hospitals and specialty clinics, and patient advocacy representatives to surface adoption barriers and care pathway realities.

Data were triangulated through cross-validation of clinical inputs, supply-chain assessments, and payer perspectives to reconcile divergent viewpoints and highlight consensus-driven implications. Segmentation analysis applied diagnostic, therapeutic, and channel lenses to isolate differential needs across bradykinin receptor antagonists, C1 inhibitors, and kallikrein inhibitors as well as injectable versus oral administration, hereditary versus acquired and idiopathic disease types, and the roles of home care, hospitals, and specialty clinics. Quality control measures included methodological audits, interview verification, and iterative expert review to ensure findings are actionable and replicable.

Concluding synthesis emphasizing the interplay of therapeutic innovation, delivery models, payer engagement, and supply resilience required for meaningful angioedema care advancement

The cumulative analysis underscores a strategic inflection point for angioedema treatment where molecular innovation, delivery optimization, and ecosystem design converge to create new opportunities for improved patient outcomes and differentiated commercial success. Advances in targeted therapeutics and an increased emphasis on home-based care models are shifting clinical practice toward proactive management, while supply chain and policy dynamics require deliberate mitigation strategies to sustain access. Effective commercialization will depend not solely on molecular efficacy but on the ability to demonstrate value to payers, deliver convenient and safe administration options to patients, and ensure distribution reliability across diverse channels.

Looking ahead, organizations that couple robust clinical programs with adaptive supply chains and comprehensive patient support mechanisms will be best positioned to translate scientific progress into meaningful care improvements. Cross-disciplinary collaboration among developers, clinicians, payers, and patient groups will remain essential to align incentives and expedite adoption of therapies that reduce disease burden and enhance long-term quality of life.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Angioedema Treatment Market, by Drug Class

• 8.1. Bradykinin Receptor Antagonists
• 8.2. C1 Inhibitors
• 8.3. Kallikrein Inhibitors

9. Angioedema Treatment Market, by Administration Route

• 9.1. Injectable
• 9.2. Oral

10. Angioedema Treatment Market, by Disease Type

• 10.1. Acquired
• 10.2. Hereditary
• 10.3. Idiopathic

11. Angioedema Treatment Market, by End User

• 11.1. Home Care
• 11.2. Hospitals
• 11.3. Specialty Clinics

12. Angioedema Treatment Market, by Distribution Channel

• 12.1. Hospital Pharmacy
• 12.2. Online Pharmacy
• 12.3. Retail Pharmacy

13. Angioedema Treatment Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Angioedema Treatment Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Angioedema Treatment Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Angioedema Treatment Market

17. China Angioedema Treatment Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. Adverum Biotechnologies, Inc.
• 18.6. Argenx NV
• 18.7. AstraZeneca plc
• 18.8. Attune Pharmaceuticals, Inc.
• 18.9. Aurobindo Pharma Ltd.
• 18.10. Bayer AG
• 18.11. BioCryst Pharmaceuticals, Inc.
• 18.12. Cipla Limited
• 18.13. CSL Behring
• 18.14. Dr. Reddy's Laboratories Ltd.
• 18.15. GlaxoSmithKline plc
• 18.16. HAE Pharma LLC
• 18.17. Intellia Therapeutics, Inc.
• 18.18. Ionis Pharmaceuticals, Inc.
• 18.19. KalVista Pharmaceuticals Ltd.
• 18.20. Merck & Co., Inc.
• 18.21. Novartis AG
• 18.22. Otsuka Pharmaceutical Co., Ltd.
• 18.23. Pfizer Inc.
• 18.24. Pharming Group N.V.
• 18.25. Pharvaris Netherlands B.V.
• 18.26. Sanofi S.A.
• 18.27. Sobi
• 18.28. Takeda Pharmaceutical Company Limited
• 18.29. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ANGIOEDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL ANGIOEDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 13. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ACQUIRED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ACQUIRED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ACQUIRED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HEREDITARY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HEREDITARY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HEREDITARY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY IDIOPATHIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY IDIOPATHIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY IDIOPATHIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 50. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 51. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 52. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 53. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 54. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 55. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 56. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 57. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 58. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 59. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 60. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 61. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 62. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 63. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 64. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 65. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 66. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 67. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 68. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 69. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 70. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 71. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 72. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 73. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 74. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 75. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 76. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 77. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 78. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 79. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 80. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 81. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 82. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 83. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 84. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 85. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 86. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 87. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 88. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 89. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 90. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 91. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 92. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 93. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 94. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 95. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 96. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 97. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 98. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 99. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 100. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 101. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 102. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 103. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 104. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 105. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 106. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 107. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 108. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 109. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 110. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 111. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 112. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 113. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 114. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 115. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 116. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 117. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 118. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 119. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 120. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 121. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 122. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 123. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 124. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 125. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 126. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 127. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 128. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 129. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 130. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 131. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 132. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 133. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 134. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 135. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 136. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 137. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 138. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 139. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 140. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 141. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 142. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 143. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 144. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 145. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 146. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 147. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)